• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用多个死因编码计算美国特定部位、基于死亡证明的癌症死亡率统计数据的影响。

Impact of using multiple causes of death codes to compute site-specific, death certificate-based cancer mortality statistics in the United States.

机构信息

ICF International Inc., Bethesda, MD 20814, USA.

出版信息

Cancer Epidemiol. 2012 Feb;36(1):22-8. doi: 10.1016/j.canep.2011.07.004. Epub 2011 Sep 8.

DOI:10.1016/j.canep.2011.07.004
PMID:21907006
Abstract

BACKGROUND

Cancer mortality statistics, an important indicator for monitoring cancer burden, are traditionally restricted to instances when cancer is determined to be the underlying cause of death (UCD) based on information recorded on standard certificates of death. This study's objective was to determine the impact of using multiple causes of death codes to compute site-specific cancer mortality statistics.

METHODS

The state cancer registries of California, Colorado and Idaho provided linked cancer registry and death certificate data for individuals who died between 2002 and 2004, had at least one cancer listed on their death certificate and were diagnosed with cancer between 1993 and 2004. These linked data were used to calculate the site-specific proportion of cancers not selected as the UCD (non-UCD) among all cancer-related deaths (any mention on the death certificate). In addition, the retrospective concordance between the death certificate and the population-based cancer registry, measured as confirmations rates, was calculated for deaths with cancer as the UCD, as a non-UCD, and for any mention.

RESULTS

Overall, non-UCD deaths comprised 9.5 percent of total deaths; 11 of the 79 cancer sites had proportions greater than 3 standard deviations from 9.5 percent. The confirmation rates for UCD and for any mention did not differ significantly for any of the cancer sites.

CONCLUSION AND IMPACT

The site-specific variation in proportions and rates suggests that for a few cancer sites, death rates might be computed for both UCD and any mention of the cancer site on the death certificate. Nevertheless, this study provides evidence that, in general, restricting to UCD deaths will not under report cancer mortality statistics.

摘要

背景

癌症死亡率统计数据是监测癌症负担的一个重要指标,传统上仅限于根据死亡证明上记录的信息确定癌症是根本死因(UCD)的情况。本研究旨在确定使用多个死因代码计算特定部位癌症死亡率统计数据的影响。

方法

加利福尼亚州、科罗拉多州和爱达荷州的州癌症登记处提供了 2002 年至 2004 年间死亡、至少有一种癌症在死亡证明上列出且在 1993 年至 2004 年间被诊断患有癌症的个体的癌症登记处和死亡证明的链接数据。这些链接数据用于计算所有与癌症相关的死亡(死亡证明上的任何提及)中未被选为 UCD(非 UCD)的特定部位癌症的比例。此外,还计算了作为 UCD、非 UCD 和任何提及的癌症死亡的死亡证明与基于人群的癌症登记处之间的回顾性一致性,以确认率表示。

结果

总体而言,非 UCD 死亡占总死亡人数的 9.5%;79 个癌症部位中有 11 个部位的比例超过 9.5%的 3 个标准差。UCD 和任何提及的确认率在任何癌症部位均无显著差异。

结论和影响

特定部位的比例和速率变化表明,对于少数癌症部位,可能会根据死亡证明上 UCD 和癌症部位的任何提及来计算死亡率。然而,本研究提供的证据表明,一般来说,将 UCD 死亡限制在范围内不会少报癌症死亡率统计数据。

相似文献

1
Impact of using multiple causes of death codes to compute site-specific, death certificate-based cancer mortality statistics in the United States.使用多个死因编码计算美国特定部位、基于死亡证明的癌症死亡率统计数据的影响。
Cancer Epidemiol. 2012 Feb;36(1):22-8. doi: 10.1016/j.canep.2011.07.004. Epub 2011 Sep 8.
2
Leukemia as a cause of death among patients with myelodysplastic syndromes (MDS) in a population- based cancer registry: improving estimates of MDS-related mortality in the population.在基于人群的癌症登记处中,白血病作为骨髓增生异常综合征(MDS)患者的死因:改进人群中MDS相关死亡率的估计。
J Registry Manag. 2012 Fall;39(3):115-20.
3
Variability in cancer death certificate accuracy by characteristics of death certifiers.根据死亡证明开具者的特征,癌症死亡证明准确性存在差异。
Am J Forensic Med Pathol. 2012 Jun;33(2):137-42. doi: 10.1097/PAF.0b013e318219877e.
4
Determinants and interpretation of death certificate only proportions in the initial years of newly established cancer registries.新建立的癌症登记处最初几年的死亡证明比例的决定因素和解释。
Eur J Cancer. 2013 Mar;49(4):931-7. doi: 10.1016/j.ejca.2012.09.029. Epub 2012 Oct 17.
5
A national study of the location of death for older persons with dementia.一项关于老年痴呆症患者死亡地点的全国性研究。
J Am Geriatr Soc. 2005 Feb;53(2):299-305. doi: 10.1111/j.1532-5415.2005.53118.x.
6
Using birth defects registry data to evaluate infant and childhood mortality associated with birth defects: an alternative to traditional mortality assessment using underlying cause of death statistics.利用出生缺陷登记数据评估与出生缺陷相关的婴儿及儿童死亡率:一种替代使用死亡根本原因统计数据进行传统死亡率评估的方法。
Birth Defects Res A Clin Mol Teratol. 2007 Nov;79(11):792-7. doi: 10.1002/bdra.20391.
7
Using cancer registries to assess the accuracy of primary liver or intrahepatic bile duct cancer as the underlying cause of death, 1999-2010.利用癌症登记处评估1999 - 2010年原发性肝癌或肝内胆管癌作为根本死因的准确性。
J Registry Manag. 2013 Winter;40(4):168-75.
8
Surveillance of US deaths related to myelodysplastic syndromes, and the need for linkages with central cancer registries.美国与骨髓增生异常综合征相关死亡情况的监测,以及与中央癌症登记处建立联系的必要性。
J Registry Manag. 2011 Winter;38(4):183-9.
9
Magnitude of discordance between registry data and death certificate when evaluating leading causes of death in dialysis patients.评估透析患者主要死因时,登记数据与死亡证明之间的不一致程度。
BMC Med Res Methodol. 2013 Mar 27;13:51. doi: 10.1186/1471-2288-13-51.
10
Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment.《1975 - 2002年全国癌症状况年度报告》,重点介绍基于人群的癌症治疗趋势。
J Natl Cancer Inst. 2005 Oct 5;97(19):1407-27. doi: 10.1093/jnci/dji289.

引用本文的文献

1
Estimating years of life lost due to premature mortality at regional level in France in 2017, using a probabilistic redistribution approach.采用概率再分配方法估算2017年法国地区层面因过早死亡导致的寿命损失年数。
BMC Public Health. 2025 Jul 3;25(1):2375. doi: 10.1186/s12889-025-23559-6.
2
Investigating years of life lost in Belgium, 2004-2019: A comprehensive analysis using a probabilistic redistribution approach.调查2004年至2019年比利时的寿命损失年数:采用概率再分配方法的综合分析。
Arch Public Health. 2023 Aug 25;81(1):160. doi: 10.1186/s13690-023-01163-7.
3
Quantifying cause-related mortality in Australia, incorporating multiple causes: observed patterns, trends and practical considerations.
量化澳大利亚的与病因相关的死亡率,纳入多种病因:观察到的模式、趋势和实际考虑。
Int J Epidemiol. 2023 Feb 8;52(1):284-294. doi: 10.1093/ije/dyac167.
4
Outcome Assessment in Epidemiological Studies of Low-Dose Radiation Exposure and Cancer Risks: Sources, Level of Ascertainment, and Misclassification.低剂量辐射暴露与癌症风险的流行病学研究中的结局评估:来源、确定程度和分类错误。
J Natl Cancer Inst Monogr. 2020 Jul 1;2020(56):154-175. doi: 10.1093/jncimonographs/lgaa007.
5
A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA.一种使用基于金纳米棒的纳米载体共递送阿霉素和小干扰RNA的胰腺癌光驱动疗法
Theranostics. 2015 Apr 20;5(8):818-33. doi: 10.7150/thno.11335. eCollection 2015.